Customized In Vivo Ocular Models ace

- By Animal Species
- By Disease

Get in Touch ace

* First Name:
* Last Name:
* Business Email:
Phone:
Company/Institution:
Job Title:
* Services of Interest: Customized Animal Models of Ocular Neovascularization
When do you expect your project to start?
Project Description:
* All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
* Tick to confirm the Research Use Only (RUO) statement.

Customized Animal Models of Ocular Neovascularization

Ace Therapeutics supports researchers with preclinical ocular neovascularization studies, providing fit-for-purpose model development and study execution in corneal, ocular-surface, retinal, and choroidal neovascularization settings. Guided by research objectives, our team helps shape study designs to characterize vascular growth, regression, and leakage over time. We provide preclinical evaluation services to support diverse therapeutic modalities and routes of administration, with integrated structural, functional, and molecular endpoints to assess efficacy and the mechanism-of-action.

Pathobiology of Ocular Neovascularization

Ocular neovascularization is the pathological formation of blood and sometimes lymphatic vessels within normally avascular ocular tissues such as the cornea, ocular surface, retina, and choroid. It can arise after inflammation, hypoxia, ischemia, or mechanical injury. Imbalance between pro-angiogenic and anti-angiogenic factors, with vascular endothelial growth factor (VEGF) signaling as a central driver, promotes endothelial activation, vessel sprouting, leakage, and tissue remodeling. Inflammatory and stromal cells sustain the angiogenic milieu, and epigenetic mechanisms modulate these responses. Preclinical animal models of ocular neovascularization are essential tools for mechanistic and therapeutic evaluation.

Fig. 1. Ocular neovascularization across the cornea, retina, and choroid. Fig. 1. Anatomical distribution and manifestations of ocular neovascularization. (Hu Q, et al., 2022)

Explore Our Animal Models of Ocular Neovascularization

At Ace Therapeutics, our preclinical platform supports the development of customized ocular neovascularization animal models across corneal, ocular-surface, retinal, and choroidal compartments in multiple species. These ocular neovascularization models allow controlled recapitulation of key pathological events such as angiogenic activation, vessel ingrowth, leakage, and tissue remodeling, creating a translational bridge between in vitro studies and in vivo pharmacology. The same framework accommodates a broad spectrum of therapeutic modalities and routes of administration, supporting side-by-side evaluation across indications or candidates.

Ocular Neovascularization Animal Model Evaluation Services

We offer integrated efficacy and mechanistic readouts for ocular neovascularization studies, turning in vivo model responses into structured, quantitative datasets. These readouts support early exploratory work, candidate comparison, and more in-depth characterization under defined dosing regimens and routes of administration.

Service Category	Available Services
Structural and Vascular Imaging	Slit-lamp and anterior-segment imaging to document corneal and ocular-surface vascular changes. Fundus photography and angiography-based evaluations to visualize lesion area and vascular leakage in the posterior segment. Optical coherence tomography (OCT) and related imaging modalities to assess retinal and choroidal thickness, edema, and neovascular complexes over time.
Histology and Tissue-Level Analyses	Standard and special staining of cornea, retina, choroid, and adjacent tissues to assess neovascularization, edema, fibrosis, and tissue integrity. Flat-mount and section-based quantification of vessel extent, density, and distribution using endothelial and lymphatic markers. Morphometric analysis of lesion size, depth, and tissue remodeling.
Molecular and Biomarker Profiling	Gene and protein expression analysis of key angiogenic, inflammatory, and matrix-remodeling pathways by qPCR, immunoassays, and immunohistochemistry. Quantification of soluble biomarkers in ocular tissues and biofluids to complement imaging and histology in neovascularization studies.

Ace Therapeutics provides an integrated preclinical solution for ocular neovascularization, combining customized animal models with flexible efficacy assessments and mechanistic analyses for diverse therapeutic approaches. Wondering how these ocular neovascularization models and readouts can support your project? Contact us to collaborate with our scientists and refine your study concepts.

References

Zhou YF, Xu MY, Shen WY, et al. Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management. Adv Healthc Mater. 2024 Jul; 13(17): e2304626.
Yang YL, Zhong JM, Cui DM, et al. Up-to-date molecular medicine strategies for management of ocular surface neovascularization. Adv Drug Deliv Rev. 2023 Oct; 201: 115084.
Hu Q, Zhang X, Sun MH, et al. Potential epigenetic molecular regulatory networks in ocular neovascularization. Front Genet. 2022 Sep 2; 13: 970224.

For Research Use Only.